No surprise: FDA hands Pain Therapeutics another slapdown on Remoxy, forcing a quick restructuring

Just as expected, the FDA has once again hit Pain Therapeutics $PTIEwith a rejection of its application to sell Remoxy. And the biotech’s CEO lashed out, calling the decision “bizarre” as it prepped a company-wide restructuring.